According to a new virological research paper published in Nature-structure and Molecular Biology, a professional academic journal of Springer Nature, through a comparative study on the structure of the novel coronavirus (SARS-CoV-2)Read More…
Mark Shotov, director of the “Vector” National Virology and Biotechnology Research Center of the Russian Federation’s Consumer Rights Protection and Public Welfare Supervision Agency, said the center had developed an intranasal novelRead More…
Sanofi Pasteur recently announced the development of a new mRNA vaccine for COVID-19. In February, Sanofi Pasteur announced that it would begin to develop a recombinant protein candidate vaccine for COVID-19. DavidRead More…
1. Introduction to COVID-19 Novel coronavirus (SARS-CoV-2) is a member of the enveloped RNA virus family, novel coronavirus, which was discovered at the end of 2019. This family of viruses includes MiddleRead More…
Adoptive T cell therapy has achieved clinical success in B cell malignant tumors. However, CAR-T cell therapy is challenged and less effective in patients with solid tumors. A key obstacle is theRead More…
Medical researchers at the University of Texas at Galveston have shown for the first time that a single higher dose of vaccination in a pregnant mouse can safely protect her and herRead More…
Recently, the US Food and Drug Administration (FDA) has approved an application for a supplementary biological product license from Sanofi’s Fluzone® High-Dose Quadrivalent (High dose tetravalent, Influenza Vaccine) for older people agedRead More…
1. RNA vaccine RNA-based vaccines have great potential as a way to treat cancer or prevent a variety of infectious diseases. As a result, many biotechnology companies are now developing this typeRead More…
Janssen Pharmaceutical recently announced that the US Food and Drug Administration (FDA) has awarded the company the breakthrough drug qualification (BTD) for prophylactic RSV advanced vaccines. It is used to prevent lowerRead More…
Recently, Elios Therapeutics released positive top-line data to evaluate the clinical trial of TLPLDC (tumor lysate, particle loading, dendritic cell) vaccine in the treatment of melanoma in phase IIb. 1.Research result ThisRead More…